Bayer/J&J Attempt At New Lands For Xarelto Backfires With MAGELLAN
This article was originally published in Pharmaceutical Approvals Monthly
NEW ORLEANS – A trial designed to expand the market for Bayer HealthCare/Johnson & Johnson’s oral anticoagulant Xarelto (rivaroxaban) instead has highlighted that the drug has a worse bleeding profile than Sanofi-Aventis’ low molecular weight heparin Lovenox (enoxparin) in patients hospitalized with acute illnesses.
You may also be interested in...
Portola prepares to launch new anticoagulant betrixaban in niche patient population of patients with acute medical illness at risk of VTE, following FDA approval, despite mixed Phase III data.
Simultaneously, partner Bayer submits applications in Europe, where rivaroxaban already is approved, for those indications and one more.
The APPRAISE-2 trial was stopped due to excess bleeding. But the study tested the drug as an add-on treatment in a high-risk population and in a marginal indication for the anticoagulant.